Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.govIdentifier |
NCT04231222
|
| gptkbp:completedIn |
March 2022
|
| gptkbp:conditionStudied |
Small Intestinal Bacterial Overgrowth
|
| gptkbp:enrollment |
142
|
| gptkbp:fullName |
Efficacy and Safety of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth (SIBO)
|
| https://www.w3.org/2000/01/rdf-schema#label |
EPOC16 (SIBO)
|
| gptkbp:intervention |
Rifaximin
|
| gptkbp:location |
gptkb:Europe
|
| gptkbp:period |
Phase 3
|
| gptkbp:result |
Normalization of breath test
|
| gptkbp:sponsor |
Alfasigma S.p.A.
|
| gptkbp:startDate |
January 2020
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:Psion_Series_5mx
|
| gptkbp:bfsLayer |
7
|